Feasibility of an evidence-based multidisciplinary care framework in a Pompe disease carrier pregnancy ‒ a case report
DOI:
https://doi.org/10.15584/ejcem.2026.3.14Keywords:
lysosomal storage disorders, multidisciplinary care, Pompe disease, pregnancy management, prenatal diagnosisAbstract
Introduction and aim. Pompe disease-carrier pregnancies present complex management challenges that require integrated genetic, biochemical, and psychosocial interventions. The current literature lacks comprehensive management frameworks that address the multifaceted needs of these high-risk pregnancies.
Description of the case. We report the treatment of a 31-year-old South Asian woman with three previous pregnancies affected by Pompe disease using a systematic multidisciplinary protocol developed following the current European Reference Network guidelines. Both partners were compound heterozygous carriers with documented pathogenic variants. The protocol integrated early genetic diagnosis through sampling of the chorionic villus, systematic biochemical monitoring, structured psychological support, and coordinated multidisciplinary care involving eight specialist services. Maternal psychological scores showed substantial improvement with the Edinburgh Postnatal Depression Scale decreasing from 14 to 2 (86% improvement) and the Generalized Anxiety Disorder Scale decreasing from 12 to 1 (92% improvement) after protocol-based psychological support without concurrent medication or therapy. Six-month follow-up confirmed sustained clinical and psychological benefits with normal infant development.
Conclusion. This case demonstrates the feasibility of implementing a systematic multidisciplinary care framework for Pompe disease-carrier pregnancy. Although preliminary results are encouraging, validation through larger cohort studies is necessary before widespread implementation, considering resource availability, genetic diversity, and cultural factors that may influence reproducibility in different healthcare settings.
Downloads
References
Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10(9):1339. doi:10.3390/biom10091339
Waters D, Adeloye D, Woolham D, Wastnedge E, Patel S, Rudan I. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J Glob Health. 2018;8(2):021102. doi:10.7189/jogh.08.021102
Taglia A, Picillo E, D'Ambrosio P, Cecio MR, Viggiano E, Politano L. Genetic counseling in Pompe disease. Acta Myol. 2011;30(3):179-181.
Witt S, Schuett K, Wiegand-Grefe S, Boettcher J, Quitmann J. Living with a rare disease - experiences and needs in pediatric patients and their parents. Orphanet J Rare Dis. 2023;18(1):242. doi:10.1186/s13023-023-02837-9
Talay L, Vickers M, Lu D. Nurse practitioner and general practitioner error rates in a large digital health service: a retrospective cohort analysis. Nurs Rep. 2024;14(4):3407-3416. doi:10.3390/nursrep14040246
Parenti G, Fecarotta S, Alagia M, et al. The European reference network for metabolic diseases (MetabERN) clinical pathway recommendations for Pompe disease (acid maltase deficiency, glycogen storage disease type II). Orphanet J Rare Dis. 2024;19(1):408. doi:10.1186/s13023-024-03373-w
Yoo H, Ahn S. Effects of nonpharmacological interventions on the psychological health of high-risk pregnant women: a systematic review and meta-analysis. Korean J Women Health Nurs. 2021;27(3):180-195. doi:10.4069/kjwhn.2021.09.17
Añón-Oñate I, Cáliz-Cáliz R, Rosa-Garrido C, Pérez-Galán MJ, Quirosa-Flores S, Pancorbo-Hidalgo PL. Multidisciplinary unit improves pregnancy outcomes in women with rheumatic diseases and hereditary thrombophilias: an observational study. J Clin Med. 2021;10(7):1487. doi:10.3390/jcm10071487
Van den Veyver IB, Chandler N, Wilkins-Haug LE, Wapner RJ, Chitty LS; ISPD Board of Directors. International Society for Prenatal Diagnosis updated position statement on the use of genome-wide sequencing for prenatal diagnosis. Prenat Diagn. 2022;42(6):796-803. doi:10.1002/pd.6157
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 European Journal of Clinical and Experimental Medicine

This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.




